, Nous avons comparé les données intrinsèques des patient entres ceux qui avaient eu une rechute locorégionale (RLR+) et ceux qui n'en avaient pas (RLR-)

, Les patients RLR+ étaient légèrement moins âgés 61,7 ans (±4) contre 66,9 ans (±8,6) dans le groupe RLR-sans que cette différence ne soit significative, vol.29, p.95

L. De, Charlson médian ne variait pas significativement (p= 0,7) entre les 2 groupes

, 3 %) dans le groupe RLR+, cela représentait 2 patients et cette différence, en analyse univariée, n'était pas significative (p= 0,06). En revanche, en analyse multivariée, proches collatéraux de plus de 55 ans dans le groupe RLR-et 1 patient, vol.33

, Trois patients avaient un antécédent familial après 55 ans dans le groupe RLR-sans en observer dans le groupe RLR+, cette différence n'était pas significative

. Dans-le-groupe-rlr-, 2 %) avaient des antécédents d'infections uro-génitales, contre 1 patient dans le groupe RLR+ (ce qui représentaient 33,3 % du groupe RLR+) cette différence n'était pas significative, vol.6

. Dans-le-groupe-rlr, ) avaient des antécédents de PIN haut grade dans lors de biopsies antérieures, mais aucun dans le groupe RLR+ cette différence n'était pas significative (p= 1)

, Nous avons comparé les données intrinsèques des patient entres ceux qui avaient eu une rechute clinique (RC+) et ceux qui n'en avaient pas (RC-)

, Les patients RC+ étaient légèrement moins âgés 63,5 ans (±4) contre 67 ans (±7,6) dans le groupe RC-sans que cette différence ne soit significative, vol.96, p.95

L. De, Charlson médian ne variait pas significativement (p= 0,97) entre les 2 groupes

. Rc+, En revanche, en analyse multivariée, cette différence était significative l'odds ratio

, Trois patients avaient un antécédent familial après 55 ans dans le groupe RC-sans en observer dans le groupe RC+, cette différence n'était pas significative (p= 1) en analyse univariée

. Dans-le-groupe-rc-, 7 %) avaient des antécédents d'infections uro-génitales, contre 1 patient dans le groupe RC+ (ce qui représentaient 20 % du groupe RC+) cette différence n'était pas significative (p= 1). L'odds ratio, vol.5

. Dans-le-groupe-rc, 6 %) avaient des antécédents de PIN haut grade dans lors de biopsies antérieures, mais aucun dans le groupe RC+ cette différence n'était pas significative (p= 1). Elle ne l'était pas non plus en analyse multivariée avec un

, En effet, les patient GS-semblaient être plus âgés (67,5 (±8,8)) que les patients GS+ (62,6 (±6)), cela pouvait s'expliquer par le fait que les patients plus jeunes étaient plus demandeurs quant à la fonction sexuelle, Parmi tous les facteurs de risques mentionnés, l'âge, semblait être en analyse univariée (p= 0,022) et multivariée (différence moyenne, vol.4

, La présence d'antécédents d'infections uro-génitales n'était pas significativement différente

, Elle ne l'était pas non plus en analyse multivariée OR 1,2 avec un IC95%

, L'absence de facteurs de risques cardiovasculaires n'était pas significativement différente

E. ,

&. En-analyse-univariée and . Hta, de diabète (p= 0,7), de dyslipidémie (p= 0,7) et d'obésité (p= 0,4), n'étaient pas significativement différent en répartition entre les groupes GS-et GS+. L'analyse multivariée ne changeait pas la donne avec des intervalles de confiance

, En revanche, les volumes prostatiques moyens au TR et à l'échographie endorectale ou à l'IRM étaient plus importants dans le groupe GS+

G. S. Dans-le-groupe, ±9) et 36,5 cc (±13)) avec respectivement p= 0,0001 et p= 0,024. Comme le montre plus haut la courbe de Forest plot (Figure 22), l'analyse multivariée restait significative avec des différence moyennes de -18,3 cc IC95%

, 03) et multivariée (IC95% [1,3 ;38]) pour le volume à l'échographie sus-pubienne mais les proportions étaient inversées avec des volumes moyens plus importants dans le groupe GS-(52 cc (±12)) que dans le groupe GS+ (32 cc (±21)). Cette évaluation du volume est moins fiable, La différence était significative aussi en analyse univariée

, Probablement qu'un volume important rendait la prostatectomie moins simple (avec plus de saignement per-opératoire gênant la visibilité pour la préservation nerveuse) et la dose délivrée par RTE plus importante ce qui pouvait expliquer les effets secondaires sexuels plus importants pour les gros volumes prostatiques

R. Bibliographiques,

F. Rozeta, *. , C. Hennequina, J. Beauvala, P. Beuzeboca et al., aComité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11 rue Viète, Progrès en Urologie, vol.27, pp.95-143, 2016.

C. Fitzmaurice, T. F. Akinyemiju, F. Lami, T. Alam, R. Alizadeh-navaei et al., Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study, JAMA Oncol, issue.2, 2018.

D. Sur,

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer. 1 mars, vol.136, issue.5, pp.359-86, 2015.

P. Grosclaude, A. Belot, D. Marliac, L. Remontet, L. Leone et al., Le cancer de la prostate, évolution de l'incidence et de la mortalité en France entre, Progrès en Urologie. 1 juill, vol.25, issue.9, pp.536-578, 1980.

, Projection de l'incidence et de la mortalité par cancer urologique en France en 2012, Progrès en Urologie, vol.23, pp.57-65, 2013.

K. Hemminki, Familial risk and familial survival in prostate cancer, World J Urol. 1 avr, vol.30, issue.2, pp.143-151, 2012.

K. F. Jansson, O. Akre, H. Garmo, A. Bill-axelson, J. Adolfsson et al., Concordance of Tumor Differentiation Among Brothers with Prostate Cancer, European Urology, vol.62, issue.4, pp.656-61, 2012.

M. Randazzo, A. Müller, S. Carlsson, D. Eberli, A. Huber et al., A Positive Family History as risk factor for Prostate Cancer in a Population-based Study with organized PSAScreening: Results of the Swiss ERSPC (Aarau), BJU Int. avr, vol.117, issue.4, pp.576-83, 2016.

D. Tan, T. Mok, and T. R. Rebbeck, Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. JCO. 1 janv, vol.34, issue.1, pp.91-101, 2016.

N. Breslow, C. W. Chan, G. Dhom, R. Drury, .. B. Franks et al., Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, International Journal of Cancer, vol.15, issue.5, pp.680-688, 1977.

M. F. Leitzmann and S. Rohrmann, Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates, Clin Epidemiol, vol.4, pp.1-11, 2012.

G. P. Haas, N. Delongchamps, O. W. Brawley, C. Y. Wang, and G. De-la-roza, The worldwide epidemiology of prostate cancer: perspectives from autopsy studies, Can J Urol. févr, vol.15, issue.1, pp.3866-71, 2008.

K. Bell, D. Mar, C. Wright, G. Dickinson, J. Glasziou et al., Prevalence of incidental prostate cancer: A systematic review of autopsy studies, Int J Cancer, vol.137, issue.7, pp.1749-57, 2015.

K. Esposito, P. Chiodini, A. Capuano, G. Bellastella, M. I. Maiorino et al., Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis, J Endocrinol Invest. févr, vol.36, issue.2, pp.132-141, 2013.

A. Blanc-lapierre, A. Spence, P. I. Karakiewicz, A. Aprikian, F. Saad et al., Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada, vol.15, p.913, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-01351901

A. C. Vidal, L. E. Howard, D. M. Moreira, R. Castro-santamaria, G. L. Andriole et al., Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study, Cancer Epidemiol Biomarkers Prev. 1 déc, vol.23, issue.12, pp.2936-2978, 2014.

N. M. Davies, T. R. Gaunt, S. J. Lewis, J. Holly, J. L. Donovan et al., The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium, Cancer Causes Control, vol.26, issue.11, pp.1603-1619, 2015.

, Metformin Use and Prostate Cancer Risk, European Urology. 1 déc, vol.66, issue.6, pp.1012-1032, 2014.

S. J. Freedland, R. J. Hamilton, L. Gerber, L. L. Banez, D. M. Moreira et al., Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study, Prostate Cancer and Prostatic Diseases. sept, vol.16, issue.3, pp.254-263, 2013.

B. S. Kramer, K. L. Hagerty, S. Justman, M. R. Somerfield, P. C. Albertsen et al., Use of 5-?-Reductase Inhibitors for Prostate Cancer Chemoprevention, Clinical Practice Guideline. JCO. 20 mars, vol.27, issue.9, pp.1502-1518, 2008.

G. L. Andriole, D. G. Bostwick, O. W. Brawley, L. G. Gomella, M. Marberger et al., Effect of dutasteride on the risk of prostate cancer, N Engl J Med. 1 avr, vol.362, issue.13, pp.1192-202, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00493661

I. M. Thompson, P. J. Goodman, C. M. Tangen, M. S. Lucia, G. J. Miller et al., The Influence of Finasteride on the Development of Prostate Cancer, New England Journal of Medicine. 17 juill, vol.349, issue.3, pp.215-239, 2003.

, Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries, The Journal of Urology. 1 janv, vol.193, issue.1, pp.80-86, 2015.

C. K. Zhou, P. H. Levine, S. D. Cleary, H. J. Hoffman, B. I. Graubard et al., Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study, Am J Epidemiol. 1 févr, vol.183, issue.3, pp.210-217, 2016.

, Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up, European Urology. 1 déc, vol.70, issue.6, pp.974-82, 2016.

, Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: A systematic review, Maturitas. 1 août, vol.72, issue.4, pp.269-76, 2012.

P. Chen, W. Zhang, X. Wang, K. Zhao, D. S. Negi et al., Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis, Medicine (Baltimore). août, vol.94, issue.33, p.1260, 2015.

B. A. Dickerman, S. C. Markt, M. Koskenvuo, E. Pukkala, L. A. Mucci et al., Alcohol intake, drinking patterns, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins, Cancer Causes Control. 1 sept, vol.27, issue.9, pp.1049-58, 2016.

, A Systematic Review and Meta-analysis of Tobacco Use and Prostate Cancer Mortality and Incidence in Prospective Cohort Studies, European Urology. 1 déc, vol.66, issue.6, pp.1054-64, 2014.

L. Yupeng, Z. Yuxue, L. Pengfei, C. Cheng, Z. Yashuang et al., Cholesterol Levels in Blood and the Risk of Prostate Cancer: A Meta-analysis of 14 Prospective Studies, Cancer Epidemiol Biomarkers Prev. 1 juill, vol.24, issue.7, pp.1086-93, 2015.

D. D. Alexander, J. K. Bassett, D. L. Weed, E. C. Barrett, H. Watson et al., Analysis of LongChain Omega-3 Polyunsaturated Fatty Acids (LC?-3PUFA) and Prostate Cancer, Nutr Cancer, vol.67, issue.4, pp.543-54, 2015.

G. Lippi and C. Mattiuzzi, Fried food and prostate cancer risk: systematic review and meta-analysis, International Journal of Food Sciences and Nutrition, vol.4, issue.5, pp.587-596, 2015.

L. C. Bylsma and D. D. Alexander, A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer, Nutrition Journal. 21 déc, vol.14, issue.1, p.125, 2015.

S. M. Lippman, E. A. Klein, P. J. Goodman, M. S. Lucia, I. M. Thompson et al., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA. 7 janv, vol.301, issue.1, pp.39-51, 2009.

W. Q. Lian, F. Luo, X. L. Song, Y. J. Lu, and S. C. Zhao, Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies., Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies, Med Sci Monit, vol.21, pp.1895-910, 1902.

T. Huang, Y. Yan, Z. Guo, X. Zhang, H. Liu et al., Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies, Int Urol Nephrol. 1 sept, vol.46, issue.9, pp.1715-1743, 2014.

, The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of, Prostate Cancer Detection on Biopsy. Urology, vol.84, issue.5, pp.1073-80, 2014.

G. L. Andriole, E. D. Crawford, R. L. Grubb, S. S. Buys, D. Chia et al., Mortality results from a randomized prostate-cancer screening trial, N Engl J Med. 26 mars, vol.360, issue.13, pp.1310-1319, 2009.

F. H. Schröder, J. Hugosson, M. J. Roobol, T. Tammela, S. Ciatto et al., Screening and prostate-cancer mortality in a randomized European study, N Engl J Med. 26 mars, vol.360, issue.13, pp.1320-1328, 2009.

, Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer de la prostate, Progrès en Urologie, vol.27, pp.95-143, 2016.

, Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or lesS, The Journal of Urology. 1 mars, vol.161, issue.3, pp.835-844, 1999.

, Prostate Cancer Detected by Digital Rectal Examination Only. Urology. 1 déc, vol.70, issue.6, pp.1117-1137, 2007.

, The Role of the Digital Rectal Examination in Subsequent Screening Visits in the European Randomized Study of Screening for Prostate Cancer (ERSPC), European Urology. 1 sept, vol.54, issue.3, pp.581-589, 2008.

T. A. Stamey, N. Yang, A. R. Hay, J. E. Mcneal, F. S. Freiha et al., Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate, New England Journal of Medicine, vol.317, issue.15, pp.909-925, 1987.

, Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men, The Journal of Urology. 1 mai, vol.151, issue.5, pp.1283-90, 1994.

A. Semjonow, B. Brandt, F. Oberpenning, S. Roth, and L. Hertle, Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values, Prostate Suppl, vol.7, pp.3-16, 1996.

I. M. Thompson, D. K. Pauler, P. J. Goodman, C. M. Tangen, M. S. Lucia et al., Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter, N Engl J Med. 27 mai, vol.350, issue.22, pp.2239-2285, 2004.

, Validation of Pretreatment Nomograms for Predicting Indolent Prostate Cancer: Efficacy in Contemporary Urological Practice, The Journal of Urology. 1 juill, vol.180, issue.1, pp.150-154, 2008.

, Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer, The Journal of Urology. 1 mars, vol.147, issue.3, pp.815-821, 1992.

, Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy, Urology. 1 juill, vol.105, pp.123-131, 2017.

O. Gustafsson, E. Mansour, U. Norming, A. Carlsson, M. Törnblom et al., Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men, Scand J Urol Nephrol. déc, vol.32, issue.6, pp.373-380, 1998.

M. Lujan, A. Paez, L. Llanes, E. Miravalles, and A. Berenguer, Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer? Prostate Cancer and Prostatic Diseases, sept, vol.4, issue.3, pp.146-155, 2001.

T. Nordström, O. Akre, M. Aly, H. Grönberg, and M. Eklund, Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer and Prostatic Diseases, avr, vol.21, issue.1, pp.57-63, 2018.

N. Mottet and J. Irani, Place de la surveillance active dans le cancer de la prostate : présentation du protocole français: Active surveillance in prostate cancer: the French protocol, Progrès en Urologie -FMC. 1 déc, vol.18, issue.4, pp.12-18, 2008.

, Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time. The Journal of Urology. 1 juin, vol.179, issue.6, pp.2181-2187, 2008.

A. V. D&apos;amico and G. E. Hanks, Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer, vol.72, pp.2638-2681, 1993.

A. V. D&apos;amico, K. Cote, M. Loffredo, A. A. Renshaw, and D. Schultz, Determinants of prostate cancerspecific survival after radiation therapy for patients with clinically localized prostate cancer, J Clin Oncol. 1 déc, vol.20, issue.23, pp.4567-73, 2002.

H. Schmid, J. E. Mcneal, and T. A. Stamey, Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume, Cancer. 15 mars, vol.71, issue.6, pp.2031-2071, 1993.

, PSA Doubling Time, and PSA velocity, European Urology, vol.54, issue.5, pp.976-983, 2008.

, Current Applications for Prostate-Specific Antigen Doubling Time, European Urology. 1 août, vol.54, issue.2, pp.291-302, 2008.

M. F. O&apos;brien, A. M. Cronin, P. A. Fearn, B. Smith, J. Stasi et al., Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy, J Clin Oncol. 1 août, vol.27, issue.22, pp.3591-3598, 2009.

A. J. Vickers, C. Savage, M. F. O&apos;brien, and H. Lilja, Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer, J Clin Oncol. 20 janv, vol.27, issue.3, pp.398-403, 2009.

W. J. Catalona, A. W. Partin, K. M. Slawin, M. K. Brawer, R. C. Flanigan et al., Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial, JAMA. 20 mai, vol.279, pp.1542-1549, 1998.

J. I. Epstein, L. Egevad, M. B. Amin, B. Delahunt, J. R. Srigley et al., Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System, International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of, vol.40, pp.244-52, 2014.

A. V. D&apos;amico, R. Whittington, S. B. Malkowicz, D. Schultz, K. Blank et al., Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer, JAMA. 16 sept, vol.280, issue.11, pp.969-74, 1998.

, Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era, The Journal of Urology. 1 déc, vol.166, issue.6, pp.2185-2193, 2001.

, Résultats carcinologiques après prostatectomie totale pour cancer : validation française de la classification de D'Amico, Progrès en Urologie. 1 déc, vol.20, issue.13, pp.1206-1218, 2010.

, Mayo Clinic Validation of the D'Amico Risk Group Classification for Predicting Survival Following Radical Prostatectomy, The Journal of Urology. 1 avr, vol.179, issue.4, pp.1354-61, 2008.

, 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience, International Journal of Radiation Oncology*Biology*Physics. 1 janv, vol.70, issue.5, pp.57-64, 2007.

M. R. Cooperberg, D. J. Pasta, E. P. Elkin, M. S. Litwin, D. M. Latini et al., The UCSF Cancer of the Prostate Risk Assessment (CAPRA) Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy, J Urol. juin, vol.173, issue.6, pp.1938-1980, 2005.

M. R. Cooperberg, J. F. Hilton, and P. R. Carroll, The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy, Cancer, vol.15, issue.22, pp.5039-5085, 2011.

S. Professionals, Prostate Cancer

. Uroweb,

K. A. Lindert, J. N. Kabalin, and M. K. Terris, Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy, J Urol. juill, vol.164, issue.1, pp.76-80, 2000.

R. Briffaux, P. Coloby, F. Bruyere, F. Ouaki, C. Pires et al., One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy, BJU Int. avr, vol.103, issue.8, pp.1069-1073, 2009.
DOI : 10.1111/j.1464-410x.2008.08128.x

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1464-410X.2008.08128.x

F. Bruyère, A. Sotto, L. Escaravage, G. Cariou, J. Mignard et al.,

, Prog Urol. févr, vol.20, issue.2, pp.101-109, 2010.

O. Wegelin, H. Van-melick, L. Hooft, J. Bosch, H. B. Reitsma et al., Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?, Eur Urol, vol.71, issue.4, pp.517-548, 2017.

P. Puech, O. Rouvière, R. Renard-penna, A. Villers, P. Devos et al., Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study, Radiology. août, vol.268, issue.2, pp.461-470, 2013.

J. S. Wysock, A. B. Rosenkrantz, W. C. Huang, M. D. Stifelman, H. Lepor et al., A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial, Eur Urol. août, vol.66, issue.2, pp.343-51, 2014.

C. Arsov, R. Rabenalt, D. Blondin, M. Quentin, A. Hiester et al., Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRIultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies, Eur Urol, vol.68, issue.4, pp.713-733, 2015.

, Prostate Testing for Cancer and Treatment (ProtecT) Feasibility Study

D. Sur,

K. Eichler, S. Hempel, J. Wilby, L. Myers, L. M. Bachmann et al., Diagnostic Value of Systematic Biopsy Methods in the Investigation of Prostate Cancer: A Systematic Review, The Journal of Urology. 1 mai, vol.175, issue.5, pp.1605-1617, 2006.

S. F. Shariat and C. G. Roehrborn, Using Biopsy to Detect Prostate Cancer, Rev Urol, vol.10, issue.4, pp.262-80, 2008.

B. Turkbey, H. Mani, V. Shah, A. R. Rastinehad, M. Bernardo et al., Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds, J Urol, vol.186, issue.5, pp.1818-1842, 2011.

K. M. Selnaes, A. Heerschap, L. R. Jensen, M. Tessem, G. Schweder et al., Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology, Invest Radiol, vol.47, issue.11, pp.624-657, 2012.

F. Bratan, E. Niaf, C. Melodelima, A. L. Chesnais, R. Souchon et al., Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study, Eur Radiol. juill, vol.23, issue.7, pp.2019-2048, 2013.

J. D. Le, N. Tan, E. Shkolyar, D. Y. Lu, L. Kwan et al., Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology, Eur Urol. mars, vol.67, issue.3, pp.569-76, 2015.
DOI : 10.1016/j.eururo.2014.08.079

J. J. Fütterer, A. Briganti, D. Visschere, P. Emberton, M. Giannarini et al., Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature, Eur Urol. déc, vol.68, issue.6, pp.1045-53, 2015.

H. U. Ahmed, . El-shater, A. Bosaily, L. C. Brown, R. Gabe et al., Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study, Lancet, vol.25, pp.815-837, 2017.

A. Van-hove, P. Savoie, C. Maurin, S. Brunelle, G. Gravis et al., Comparison of imageguided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies, World J Urol. août, vol.32, issue.4, pp.847-58, 2014.

I. G. Schoots, M. J. Roobol, D. Nieboer, C. H. Bangma, E. W. Steyerberg et al., Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis, Eur Urol. sept, vol.68, issue.3, pp.438-50, 2015.

M. Valerio, I. Donaldson, M. Emberton, B. Ehdaie, B. A. Hadaschik et al., Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review, Eur Urol. juill, vol.68, issue.1, pp.8-19, 2015.

M. M. Siddiqui, S. Rais-bahrami, B. Turkbey, A. K. George, J. Rothwax et al., Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer, JAMA. 27 janv, vol.313, issue.4, pp.390-397, 2015.

O. Wegelin, H. Van-melick, L. Hooft, J. Bosch, H. B. Reitsma et al.,

, Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?, Eur Urol, vol.71, issue.4, pp.517-548, 2017.

S. Abuzallouf, I. Dayes, and H. Lukka, Baseline staging of newly diagnosed prostate cancer: a summary of the literature, The Journal of Urology. 1 juin, vol.171, issue.6, pp.2122-2129, 2004.

B. Kiss, H. C. Thoeny, and U. E. Studer, Current Status of Lymph Node Imaging in Bladder and Prostate Cancer, Urology, vol.96, pp.1-7, 2016.

A. M. Hövels, . Heesakkers-r-a.-m, E. M. Adang, G. J. Jager, S. Strum et al., The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol. avr, vol.63, issue.4, pp.387-95, 2008.

M. G. Harisinghani, J. Barentsz, P. F. Hahn, W. M. Deserno, S. Tabatabaei et al., Noninvasive detection of clinically occult lymph-node metastases in prostate cancer, N Engl J Med. 19 juin, vol.348, issue.25, pp.2491-2500, 2003.

R. C. Flanigan, T. C. Mckay, M. Olson, T. V. Shankey, J. Pyle et al., Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy, Urology. sept, vol.48, issue.3, pp.428-460, 1996.

R. Tiguert, E. L. Gheiler, M. V. Tefilli, P. Oskanian, M. Banerjee et al., Lymph node size does not correlate with the presence of prostate cancer metastasis, Urology. févr, vol.53, issue.2, pp.367-71, 1999.

L. Spevack, L. T. Killion, J. C. West, G. M. Rooker, E. A. Brewer et al., Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models, Int J Radiat Oncol Biol Phys. 1 févr, vol.34, issue.3, pp.543-550, 1996.

G. Shen, H. Deng, S. Hu, and Z. Jia, Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a metaanalysis. Skeletal Radiol, vol.43, pp.1503-1516, 2014.

A. Briganti, N. Passoni, M. Ferrari, U. Capitanio, N. Suardi et al., When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool, Eur Urol. avr, vol.57, issue.4, pp.551-559, 2010.

C. Brogsitter, K. Zöphel, J. Kotzerke, and . 18f-choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients, Eur J Nucl Med Mol Imaging. juill, vol.40, issue.1, pp.18-27, 2013.
DOI : 10.1007/s00259-013-2358-2

M. H. Poulsen, K. Bouchelouche, P. F. Høilund-carlsen, H. Petersen, O. Gerke et al., fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients, BJU Int. déc, vol.18, issue.11, pp.1666-71, 2012.

F. E. Von-eyben and K. Kairemo, Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer, Nucl Med Commun. mars, vol.35, issue.3, pp.221-251, 2014.

J. Pinaquy, D. Clermont-galleran, H. Pasticier, G. Rigou, G. Alberti et al., Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusionweighted imaging for staging in patients with high-risk prostate cancer, Prostate. 15 févr, vol.75, issue.3, pp.323-354, 2015.

M. M. Heck, M. Souvatzoglou, M. Retz, R. Nawroth, H. Kübler et al., Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients, Eur J Nucl Med Mol Imaging. avr, vol.41, issue.4, pp.694-701, 2014.

T. Budiharto, S. Joniau, E. Lerut, L. Van-den-bergh, F. Mottaghy et al., Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusionweighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases, Eur Urol. juill, vol.60, issue.1, pp.125-155, 2011.

L. Van-den-bergh, E. Lerut, K. Haustermans, C. M. Deroose, R. Oyen et al., Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement, Urol Oncol. mars, vol.33, issue.3, pp.109-132, 2015.

P. C. Albertsen, Observational studies and the natural history of screen-detected prostate cancer, Curr Opin Urol. mai, vol.25, issue.3, pp.232-239, 2015.

J. Adolfsson, Watchful waiting and active surveillance: the current position, BJU Int. juill, vol.102, issue.1, pp.10-14, 2008.
DOI : 10.1111/j.1464-410x.2008.07585.x

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1464-410X.2008.07585.x

G. W. Chodak, R. A. Thisted, G. S. Gerber, J. E. Johansson, J. Adolfsson et al., Results of conservative management of clinically localized prostate cancer, N Engl J Med. 27 janv, vol.330, issue.4, pp.242-250, 1994.

G. Sandblom, M. Dufmats, and E. Varenhorst, Long-term survival in a Swedish population-based cohort of men with prostate cancer, Urology. 1 sept, vol.56, issue.3, pp.442-449, 2000.

J. E. Johansson, H. O. Adami, S. O. Andersson, R. Bergström, U. B. Krusemo et al., Natural history of localised prostatic cancer. A population-based study in 223 untreated patients, Lancet. 15 avr, vol.1, issue.8642, pp.799-803, 1989.

A. Bill-axelson, L. Holmberg, M. Ruutu, M. Häggman, S. Andersson et al., Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med. 12 mai, vol.352, pp.1977-84, 2005.
DOI : 10.1056/nejmoa1011967

E. Jonsson, H. P. Sigbjarnarson, J. Tomasson, K. R. Benediktsdottir, L. Tryggvadottir et al., Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987, Scand J Urol Nephrol, vol.40, issue.4, pp.265-71, 2006.

J. Adolfsson, B. Tribukait, and S. Levitt, The 20-Yr outcome in patients with well-or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity, Eur Urol, vol.52, issue.4, pp.1028-1063, 2007.

G. L. Lu-yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin et al., Outcomes of localized prostate cancer following conservative management, JAMA. 16 sept, vol.302, issue.11, pp.1202-1211, 2009.
DOI : 10.1001/jama.2009.1348

URL : https://jamanetwork.com/journals/jama/articlepdf/184588/joc90095_1202_1209.pdf

P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, H. Li et al., Impact of comorbidity on survival among men with localized prostate cancer, J Clin Oncol. 1 avr, vol.29, issue.10, pp.1335-1376, 2011.

F. C. Hamdy, J. L. Donovan, J. A. Lane, M. Mason, C. Metcalfe et al., 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer, N Engl J Med, vol.13, issue.15, pp.1415-1439, 2016.

L. Klotz, D. Vesprini, P. Sethukavalan, V. Jethava, L. Zhang et al., Long-term follow-up of a large active surveillance cohort of patients with prostate cancer, J Clin Oncol. 20 janv, vol.33, issue.3, pp.272-279, 2015.

T. Yamamoto, B. Musunuru, D. Vesprini, L. Zhang, G. Ghanem et al., Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance, J Urol. mai, vol.195, issue.5, pp.1409-1423, 2016.

S. Loeb, S. M. Bruinsma, J. Nicholson, A. Briganti, T. Pickles et al., Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification, Eur Urol. avr, vol.67, issue.4, pp.619-645, 2015.

F. B. Thomsen, K. Brasso, L. H. Klotz, M. A. Røder, K. D. Berg et al., Active surveillance for clinically localized prostate cancer--A systematic review, Journal of Surgical Oncology. 1 juin, vol.109, issue.8, pp.830-835, 2014.

Y. Ha, J. Yu, A. H. Salmasi, N. Patel, J. Parihar et al., Prostate-specific antigen density toward a better cutoff to identify better candidates for active surveillance, Urology. août, vol.84, issue.2, pp.365-71, 2014.

C. Morash, R. Tey, C. Agbassi, L. Klotz, T. Mcgowan et al., Active surveillance for the management of localized prostate cancer: Guideline recommendations, Can Urol Assoc J. juin, vol.9, issue.5-6, pp.171-179, 2015.

A. C. Raldow, D. Zhang, M. Chen, M. H. Braccioforte, B. J. Moran et al., Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer, JAMA Oncol. juin, vol.1, issue.3, pp.334-374, 2015.

H. B. Musunuru, T. Yamamoto, L. Klotz, G. Ghanem, A. Mamedov et al., Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience, J Urol. déc, vol.196, issue.6, pp.1651-1659, 2016.

N. Lawrentschuk, M. A. Haider, N. Daljeet, A. Evans, A. Toi et al., Prostatic evasive anterior tumours »: the role of magnetic resonance imaging, BJU Int. mai, vol.105, issue.9, pp.1231-1237, 2010.

I. G. Schoots, N. Petrides, F. Giganti, L. P. Bokhorst, A. Rannikko et al., Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review, Eur Urol. avr, vol.67, issue.4, pp.627-663, 2015.

R. R. Pessoa, P. C. Viana, R. L. Mattedi, G. B. Guglielmetti, M. D. Cordeiro et al., Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance, BJU Int, vol.119, issue.4, pp.535-577, 2017.

M. Kamrava, A. U. Kishan, D. J. Margolis, J. Huang, F. Dorey et al., Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer, Pract Radiat Oncol. déc, vol.5, issue.6, pp.411-417, 2015.

A. Ouzzane, R. Renard-penna, F. Marliere, P. Mozer, J. Olivier et al., Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies, J Urol. août, vol.194, issue.2, pp.350-356, 2015.

M. R. Da-rosa, L. Milot, L. Sugar, D. Vesprini, H. Chung et al., A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance, J Magn Reson Imaging. janv, vol.41, issue.1, pp.220-225, 2015.

T. M. Ma, J. J. Tosoian, E. M. Schaeffer, P. Landis, S. Wolf et al., The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance, Eur Urol, vol.71, issue.2, pp.174-80, 2017.

H. Abdi, F. Pourmalek, H. Zargar, T. Walshe, A. C. Harris et al., Multiparametric magnetic resonance imaging enhances detection of significant tumor in patients on active surveillance for prostate cancer, Urology. févr, vol.85, issue.2, pp.423-431, 2015.

P. Recabal, M. Assel, D. D. Sjoberg, D. Lee, V. P. Laudone et al., The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance, J Urol. août, vol.196, issue.2, pp.374-81, 2016.

A. Heidenreich, J. Bellmunt, M. Bolla, S. Joniau, M. Mason et al., EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease, Eur Urol. janv, vol.59, issue.1, pp.61-71, 2011.

W. Diaz, A. Shakir, N. A. George, A. K. Rais-bahrami, S. Turkbey et al., Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance, Urol Oncol. mai, vol.33, issue.5, pp.202-203, 2015.

E. R. Felker, J. Wu, S. Natarajan, D. J. Margolis, S. S. Raman et al., Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value, J Urol. mai, vol.195, issue.5, pp.1421-1428, 2016.

C. M. Moore, F. Giganti, P. Albertsen, C. Allen, C. Bangma et al., Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force, Eur Urol, vol.71, issue.4, pp.648-55, 2017.

F. J. Bianco, P. T. Scardino, and E. Jasalomon, Long-term Cancer Control and Recovery of Sexual and Urinary Function, Urology. 1 févr, vol.71, issue.2, p.362, 2008.

J. Droz, L. Balducci, M. Bolla, M. Emberton, J. M. Fitzpatrick et al., Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults, Crit Rev Oncol Hematol. janv, vol.73, issue.1, pp.68-91, 2010.

T. J. Wilt, M. K. Brawer, K. M. Jones, M. J. Barry, W. J. Aronson et al., Radical prostatectomy versus observation for localized prostate cancer, N Engl J Med, vol.367, issue.3, pp.203-216, 2012.

C. Ramsay, R. Pickard, C. Robertson, A. Close, L. Vale et al., Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer, Health Technol Assess, vol.16, issue.41, pp.1-313, 2012.

F. Arroua, H. Toledano, S. Gaillet, A. Saïdi, X. Breton et al., Radical prostatectomy with bladder neck preservation: surgical margins and urinary continence, Prog Urol. mai, vol.18, issue.5, pp.304-314, 2008.

X. Ma, K. Tang, C. Yang, G. Wu, N. Xu et al., Bladder neck preservation improves time to continence after radical prostatectomy: a systematic review and meta-analysis., Bladder neck preservation improves time to continence after radical prostatectomy: a systematic review and meta-analysis, Oncotarget, vol.7, issue.7, pp.67463-75, 2016.

J. L. Stanford, Z. Feng, A. S. Hamilton, F. D. Gilliland, R. A. Stephenson et al., Urinary and Sexual Function After Radical Prostatectomy for Clinically Localized Prostate Cancer: The Prostate Cancer Outcomes Study, JAMA. 19 janv, vol.283, issue.3, pp.354-60, 2000.

D. M. Quinlan, J. I. Epstein, B. S. Carter, and P. C. Walsh, Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles, J Urol. mai, vol.145, issue.5, pp.998-1002, 1991.

M. H. Sokoloff and C. B. Brendler, Indications and contraindications for nerve-sparing radical prostatectomy, Urol Clin North Am. août, vol.28, issue.3, pp.535-578, 2001.

P. Gontero and R. S. Kirby, Nerve-sparing radical retropubic prostatectomy: techniques and clinical considerations, Prostate Cancer Prostatic Dis, vol.8, issue.2, pp.133-142, 2005.

K. C. Zorn, A. Gallina, G. C. Hutterer, J. Walz, A. L. Shalhav et al., External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy, J Endourol, vol.21, issue.11, pp.1345-51, 2007.

T. Steuber, M. Graefen, A. Haese, A. Erbersdobler, F. Chun et al., Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy, J Urol. mars, vol.175, issue.3, pp.939-944, 2006.

N. Koutlidis, G. Fiard, N. Brichart, I. Souillac, C. Lebacle et al., A majority of useless call of an on-call urology resident: a study of the AFUF, Prog Urol. juin, vol.23, issue.7, pp.480-485, 2013.

L. Salomon, D. Azria, C. Bastide, P. Beuzeboc, L. Cormier et al., Recommendations Onco-Urology, 2010.

, Prog Urol, vol.20, pp.217-251, 2010.

R. Montironi, R. Mazzucchelli, P. Colanzi, M. Streccioni, M. Scarpelli et al., Improving inter-observer agreement and certainty level in diagnosing and grading papillary urothelial neoplasms: usefulness of a Bayesian belief network, Eur Urol. avr, vol.41, issue.4, pp.449-57, 2002.

A. E. Sehdev, C. C. Pan, and J. I. Epstein, Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma, Hum Pathol. mai, vol.32, issue.5, pp.494-503, 2001.

P. Harnden, M. D. Shelley, B. Coles, J. Staffurth, and M. D. Mason, Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis, Lancet Oncol. mai, vol.8, issue.5, pp.411-420, 2007.

J. I. Epstein, M. Amin, L. Boccon-gibod, L. Egevad, P. A. Humphrey et al., Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens, Scand J Urol Nephrol Suppl. mai, issue.216, pp.34-63, 2005.

A. Chuang and J. I. Epstein, Positive surgical margins in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy: histologic features and pitfalls, Am J Surg Pathol. août, vol.32, issue.8, pp.1201-1207, 2008.

R. A. Marks, M. O. Koch, A. Lopez-beltran, R. Montironi, B. E. Juliar et al., The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens, Hum Pathol. août, vol.38, issue.8, pp.1207-1218, 2007.

J. D. Sammon, Q. Trinh, S. Sukumar, P. Ravi, A. Friedman et al., Risk factors for biochemical recurrence following radical perineal prostatectomy in a large contemporary series: a detailed assessment of margin extent and location, Urol Oncol, vol.31, issue.8, pp.1470-1476, 2013.

C. Hennequin, S. Rivera, L. Quero, and I. Latorzeff, Prostate cancer: doses and volumes of radiotherapy. Cancer Radiother, vol.14, pp.474-482, 2010.

G. M. Duchesne and L. J. Peters, What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy, Int J Radiat Oncol Biol Phys. 1 juill, vol.44, issue.4, pp.747-755, 1999.

M. Mclean, T. Panzarella, P. R. Warde, M. Gospodarowicz, W. Duncan et al., Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate, Clin Oncol (R Coll Radiol), vol.9, issue.4, pp.226-259, 1997.

M. A. Bagshaw, Comments on the treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome--regarding Zietman, Int J Radiat Oncol Biol Phys. 15 mai, vol.32, issue.2, pp.541-544, 1995.

J. M. Crook, Y. A. Bahadur, R. G. Bociek, G. A. Perry, S. J. Robertson et al., Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen, Cancer. 15 janv, vol.79, issue.2, pp.328-364, 1997.
DOI : 10.1002/(sici)1097-0142(19970115)79:2<328::aid-cncr16>3.0.co;2-2

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/%28SICI%291097-0142%2819970115%2979%3A2%3C328%3A%3AAID-CNCR16%3E3.0.CO%3B2-2

G. E. Hanks, W. R. Lee, and T. E. Schultheiss, Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation, J Urol. août, vol.154, issue.2, pp.456-465, 1995.

D. P. Dearnaley, V. S. Khoo, A. R. Norman, L. Meyer, N. A. Tait et al., Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial, Lancet. 23 janv, vol.353, issue.9149, pp.267-72, 1999.

C. C. Ling, E. Yorke, and Z. Fuks, From IMRT to IGRT: frontierland or neverland?, Radiother Oncol. févr, vol.78, issue.2, pp.119-141, 2006.

S. A. Leibel, Z. Fuks, M. J. Zelefsky, and W. F. Whitmore, The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement, Int J Radiat Oncol Biol Phys. 1 janv, vol.28, issue.1, pp.7-16, 1994.

S. O. Asbell, J. M. Krall, M. V. Pilepich, H. Baerwald, W. T. Sause et al., Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06, Int J Radiat Oncol Biol Phys. déc, vol.15, issue.6, pp.1307-1323, 1988.

P. Pommier, S. Chabaud, J. L. Lagrange, P. Richaud, F. Lesaunier et al., Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01, J Clin Oncol. 1 déc, vol.25, issue.34, pp.5366-73, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00434646

C. A. Lawton, M. Desilvio, M. Roach, V. Uhl, R. Kirsch et al., An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions, Int J Radiat Oncol Biol Phys, vol.69, issue.3, pp.646-55, 2007.

W. D. Heemsbergen, A. Al-mamgani, A. Slot, M. Dielwart, and J. V. Lebesque, Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival, Radiother Oncol. janv, vol.110, issue.1, pp.104-113, 2014.

A. Dasu and I. Toma-dasu, Prostate alpha/beta revisited --an analysis of clinical results from 14 168 patients, Acta Oncol, vol.51, issue.8, pp.963-74, 2012.

J. F. Fowler, The radiobiology of prostate cancer including new aspects of fractionated radiotherapy, Acta Oncol, vol.44, issue.3, pp.265-76, 2005.

M. Bolla, T. M. De-reijke, G. Van-tienhoven, A. Van-den-bergh, J. Oddens et al., Duration of androgen suppression in the treatment of prostate cancer, N Engl J Med. 11 juin, vol.360, issue.24, pp.2516-2543, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00492521

C. U. Jones, D. Hunt, D. G. Mcgowan, M. B. Amin, M. P. Chetner et al., Radiotherapy and short-term androgen deprivation for localized prostate cancer, N Engl J Med. 14 juill, vol.365, issue.2, pp.107-125, 2011.

V. Beckendorf, S. Guerif, L. Prisé, E. Cosset, J. Bougnoux et al., 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial, Int J Radiat Oncol Biol Phys. 15 juill, vol.80, issue.4, pp.1056-63, 2011.

S. Peeters, W. D. Heemsbergen, P. Koper, W. Van-putten, A. Slot et al., Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy, J Clin Oncol. 1 mai, vol.24, issue.13, pp.1990-1996, 2006.

G. A. Viani, E. J. Stefano, and S. L. Afonso, Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials, Int J Radiat Oncol Biol Phys. 1 août, vol.74, issue.5, pp.1405-1423, 2009.

A. L. Zietman, K. Bae, J. D. Slater, W. U. Shipley, J. A. Efstathiou et al., Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09, J Clin Oncol. 1 mars, vol.28, issue.7, pp.1106-1117, 2010.

D. A. Kuban, L. B. Levy, M. R. Cheung, A. K. Lee, S. Choi et al., Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?, Int J Radiat Oncol Biol Phys. 1 avr, vol.79, issue.5, pp.1310-1317, 2011.

M. Bolla, P. Maingon, C. C. Villa, S. Kitsios, P. Poortmans et al., Short Androgen Suppression and Radiation Dose Escalation for Intermediate-and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991, J Clin Oncol, vol.20, issue.15, pp.1748-56, 2016.

A. Zapatero, A. Guerrero, X. Maldonado, A. Alvarez, C. Gonzalez-san-segundo et al., High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial, Lancet Oncol. mars, vol.16, issue.3, pp.320-327, 2015.

A. Kalbasi, J. Li, A. Berman, S. Swisher-mcclure, M. Smaldone et al., Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer, JAMA Oncol, vol.1, issue.7, pp.897-906, 2015.
DOI : 10.1001/jamaoncol.2015.2316

URL : https://jamanetwork.com/journals/jamaoncology/articlepdf/2396585/coi150044.pdf

A. Pollack, G. Walker, E. M. Horwitz, R. Price, S. Feigenberg et al., Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer, J Clin Oncol, vol.31, issue.31, pp.3860-3868, 2013.
DOI : 10.1200/jco.2013.51.1972

URL : http://europepmc.org/articles/pmc3805927?pdf=render

L. Incrocci, R. C. Wortel, W. G. Alemayehu, S. Aluwini, E. Schimmel et al., Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, Lancet Oncol. août, vol.17, issue.8, pp.1061-1070, 2016.
DOI : 10.1016/s1470-2045(16)30070-5

D. Dearnaley, I. Syndikus, H. Mossop, V. Khoo, A. Birtle et al., Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol. août, vol.17, issue.8, pp.1047-60, 2016.

W. R. Lee, J. J. Dignam, M. B. Amin, D. W. Bruner, D. Low et al., Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer, J Clin Oncol. 10 juill, vol.34, issue.20, pp.2325-2357, 2016.
DOI : 10.1200/jco.2016.67.0448

URL : http://europepmc.org/articles/pmc4981980?pdf=render

J. Martin, J. Frantzis, P. Chung, I. Langah, M. Crain et al., Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (A TROG-OCOG Intergroup Project), Radiother Oncol. juin, vol.107, issue.3, pp.333-341, 2013.
DOI : 10.1016/j.radonc.2013.05.015

A. Wilkins, H. Mossop, I. Syndikus, V. Khoo, D. Bloomfield et al., Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol. déc, vol.16, issue.16, pp.1605-1621, 2015.

M. Bolla, G. Van-tienhoven, W. P. Dubois, J. B. Mirimanoff, R. Storme et al., External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, vol.11, issue.11, pp.1066-73, 2010.

M. V. Pilepich, K. Winter, C. A. Lawton, R. E. Krisch, H. B. Wolkov et al., Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31, Int J Radiat Oncol Biol Phys. 1 avr, vol.61, issue.5, pp.1285-90, 2005.

M. Roach, K. Bae, J. Speight, H. B. Wolkov, P. Rubin et al., Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610, J Clin Oncol. 1 févr, vol.26, issue.4, pp.585-91, 2008.

A. V. D&apos;amico, M. Chen, A. A. Renshaw, M. Loffredo, and P. W. Kantoff, Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial, JAMA. 23 janv, vol.299, issue.3, pp.289-95, 2008.

J. W. Denham, A. Steigler, D. S. Lamb, D. Joseph, S. Turner et al., Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial, Lancet Oncol. mai, vol.12, issue.5, pp.451-460, 2011.

G. E. Hanks, External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States, NCI Monogr, issue.7, pp.75-84, 1988.

M. Bolla, H. Van-poppel, B. Tombal, K. Vekemans, D. Pozzo et al., Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911), Lancet. 8 déc, vol.380, issue.9858, pp.2018-2045, 2012.

T. Wiegel, D. Bartkowiak, D. Bottke, C. Bronner, U. Steiner et al., Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial, Eur Urol. août, vol.66, issue.2, pp.243-50, 2014.

G. P. Swanson, I. M. Thompson, C. Tangen, J. Paradelo, E. Canby-hagino et al., Update of SWOG 8794: Adjuvant Radiotherapy for pT3 Prostate Cancer Improves Metastasis Free Survival, International Journal of Radiation Oncology ? Biology ? Physics. 1 sept, vol.72, issue.1, p.31, 2008.

I. M. Thompson, C. M. Tangen, J. Paradelo, M. S. Lucia, G. Miller et al., Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial, J Urol. mars, vol.181, issue.3, pp.956-62, 2009.

C. R. Ramsay, T. E. Adewuyi, J. Gray, J. Hislop, M. Shirley et al., Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation, Health Technol Assess. juill, vol.19, issue.49, pp.1-490, 2015.

W. E. Fahmy and N. K. Bissada, Cryosurgery for prostate cancer, Arch Androl, vol.49, issue.5, pp.397-407, 2003.

J. Rees, B. Patel, R. Macdonagh, and R. Persad, Cryosurgery for prostate cancer, BJU Int. avr, vol.93, issue.6, pp.710-714, 2004.

K. Han and A. S. Belldegrun, Third-generation cryosurgery for primary and recurrent prostate cancer, BJU Int. janv, vol.93, issue.1, pp.14-22, 2004.

H. P. Beerlage, S. Thüroff, S. Madersbacher, A. R. Zlotta, G. Aus et al., Current status of minimally invasive treatment options for localized prostate carcinoma, Eur Urol. janv, vol.37, issue.1, pp.2-13, 2000.

J. H. Jung, M. C. Risk, R. Goldfarb, B. Reddy, B. Coles et al., Primary cryotherapy for localised or locally advanced prostate cancer, BJU Int. 16 août, 2018.

C. M. Moore, D. Pendse, and M. Emberton, Photodynamic therapy for prostate cancer--a review of current status and future promise, Nat Clin Pract Urol. janv, vol.6, issue.1, pp.18-30, 2009.

F. Figge, G. S. Weiland, and L. Manganiello, Studies on cancer detection and therapy; the affinity of neoplastic, embryonic, and traumatized tissue for porphyrins, metalloporphyrins, and radioactive zinc hematoporphyrin, Anat Rec. août, vol.101, issue.4, p.657, 1948.

R. Pottier and J. C. Kennedy, The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue, J Photochem Photobiol B, Biol. 1 déc, vol.8, issue.1, pp.1-16, 1990.

T. J. Dougherty, C. J. Gomer, B. W. Henderson, J. G. Kessel, D. Korbelik et al., Photodynamic therapy, J Natl Cancer Inst. 17 juin, vol.90, issue.12, pp.889-905, 1998.

G. Bozzini, P. Colin, P. Nevoux, A. Villers, S. Mordon et al., Focal therapy of prostate cancer: energies and procedures, Urol Oncol. févr, vol.31, issue.2, pp.155-67, 2013.

G. Onik, P. Mikus, and B. Rubinsky, Irreversible electroporation: implications for prostate ablation, Technol Cancer Res Treat. août, vol.6, issue.4, pp.295-300, 2007.

J. L. Donovan, F. C. Hamdy, J. A. Lane, M. Mason, C. Metcalfe et al., Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer, N Engl J Med, vol.375, issue.15, pp.1425-1462, 2016.

M. J. Resnick, T. Koyama, K. Fan, P. C. Albertsen, M. Goodman et al., Long-term functional outcomes after treatment for localized prostate cancer, N Engl J Med. 31 janv, vol.368, issue.5, pp.436-481, 2013.

J. B. Eifler, Z. Feng, B. M. Lin, M. T. Partin, E. B. Humphreys et al., An updated prostate cancer staging nomogram (Partin tables) based on cases from, BJU Int. janv, vol.111, issue.1, pp.22-31, 2006.

J. I. Epstein, P. C. Walsh, M. Carmichael, and C. B. Brendler, Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer, JAMA. 2 févr, vol.271, issue.5, pp.368-74, 1994.

O. N. Kryvenko, H. B. Carter, B. J. Trock, and J. I. Epstein, Biopsy criteria for determining appropriateness for active surveillance in the modern era, Urology. avr, vol.83, issue.4, pp.869-74, 2014.

M. Roach, G. Hanks, H. Thames, P. Schellhammer, W. U. Shipley et al., Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys. 15 juill, vol.65, issue.4, pp.965-74, 2006.

P. Beuzeboc, . Words, and . Wisdom, Re: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Eur Urol, vol.50, issue.5, pp.1121-1123, 2006.